Why the study?
The study was conducted to compare the CHA2DS2-VASc score versus the C2HEST score for predicting atrial fibrillation risk in patients with end-stage renal disease.
Does the CHA2DS2-VASc score or C2HEST score better predict the incidence of atrial fibrillation in patients with end-stage renal disease?
Does the CHA2DS2-VASc score or C2HEST score better predict the incidence of atrial fibrillation in patients with end-stage renal disease?
Both the CHA2DS2-VASc and C2HEST scores have similar, albeit modest, predictive capability for incident atrial fibrillation in patients with end-stage renal disease.
Both scores show similar modest AF discrimination in ESRD; leaves open need for better ESRD-specific tools.
PURPOSE: The authors have studied assessment of CHA2DS2-VASc score versus C2HEST score in atrial fibrillation risk prediction in end-stage renal disease patients. METHODS: The authors conducted this study by Longitudinal Health Insurance Database 2000. The authors totally enrolled 4,601 end-stage renal disease patients. The predictive capability of atrial fibrillation by using CHA2DS2-VASc and C2HEST score was estimated by area under the receiver operating characteristic curve (AUROC). RESULTS: The AUROC for CHA2DS2-VASc score in predicting atrial fibrillation events was 0.5786, and AUROC for C2HEST score for atrial fibrillation prediction was 0.5983. CONCLUSION: Both scores yield almost identical AUROC values implying no difference in predictive power. Further work is warranted to verify the prognostic value of the current scores.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: